Table 3.
Risk factors for the acquisition of secondary infection
| Risk factors | n = 94 | Odds ratio (95% CI) | P value |
|---|---|---|---|
| Demographics | |||
| Age (years)—median [IQR]2 | 70 (62–77) | 0.96 (0.92–1.01) | 0.13 |
| Male gender—no. (%) | 55 (59%) | 0.41 (0.17–0.99) | 0.05 |
| BMI—median [IQR]2 | 27.5 (24.2–30.8) | 1.007 (0.926–1.095) | 0.87 |
| Diabetes mellitus—no. (%) | 32 (34%) | 0.37 (0.15–0.91) | 0.03 |
| Hypertension—no. (%) | 58 (62%) | 0.48 (0.19–1.24) | 0.13 |
| Smoking—no. (%) | 4 (4%) | 1.12 (0.13–9.93) | 0.92 |
| Characteristics of type and severity of illness | |||
| APACHE IV score—median [IQR]2 | 46 (35–57) | 0.99 (0.96–1.02) | 0.35 |
| SOFA score on admission—median [IQR]2 | 3 (2–5) | 1.14 (0.96–1.35) | 0.13 |
| Hemodynamic assist device—no. (%) | 4 (4%) | 4.54 (0.17–122.37) | 0.37 |
| Treatment | |||
| Corticosteroids dose—median [IQR]2 | 0 (0–384) | 1.004 (1.001–1.007) | 0.004 |
| Other immunosuppressive therapies*—no. (%) | 7 (7%) | 0.59 (0.12–2.78) | 0.50 |
*Other immunosuppressive therapies included: infliximab, ruxolitinib, bortezomib, mycophenolate mofetil, azacitidine and azathioprine
*p < 0.05